Non‐inferior screen fail rate for persons under the age of 65 in an anti‐amyloid monoclonal antibody clinical trial on Alzheimer’s Disease

For the early AD study considered in this analysis, participants aged 55-64 years old did not have an inferior screen fail rate relative to participants aged 65+. Study-wide decisions to exclude participants aged 55-64 in preclinical AD may not necessarily be translatable to studies of early AD within the same class of drug and with similar pTau217 screening enrichment strategies.